Polymer-Lipid Hybrid Nanoparticles for Stable Non-Viral Gene Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for stable nanoparticle compositions that can efficiently deliver nucleic acids and small molecules for therapeutic purposes, particularly in maintaining transfection efficiency over time and at higher storage temperatures, without the use of viral proteins.
Innovation Solution
The development of polymer-lipid hybrid nanoparticles (NPs) that encapsulate therapeutic drugs, allowing for the co-delivery of genetic material and drugs using a single NP delivery system, with compositions comprising PLGA, PEI, and D-Lin-MC3-DMA, which can be lyophilized into a shelf-stable powder, maintaining stability and transfection efficiency for at least 2 years at −20°C.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If viral proteins are used for gene delivery, then transfection efficiency is improved, but immune response and safety concerns worsen
Solution Approach 1:
The patent extracts and removes viral proteins from the delivery system, replacing them with non-viral polymer-lipid hybrid nanoparticles. This extraction eliminates the harmful immune response associated with viral proteins while maintaining the essential gene delivery function through synthetic nanoparticle carriers.
Solution Approach 2:
The patent creates synthetic polymer-lipid hybrid nanoparticle copies that mimic the functional capabilities of viral delivery systems without using actual viral proteins. These copied structures replicate the transfection efficiency of viral systems while eliminating the immunogenicity through synthetic material composition.
2Stability of the object's composition
If nanoparticles are stored at low temperatures, then stability is improved, but storage cost and accessibility worsen
Solution Approach 1:
The patent changes the chemical parameters of the nanoparticle composition by incorporating specific polymers and lipids that confer thermal stability. This parameter change allows the nanoparticles to maintain stability across a broader temperature range, reducing the need for strict cold chain storage while preserving composition integrity.
Solution Approach 2:
The patent uses composite polymer-lipid hybrid materials that combine the stabilizing properties of both polymer and lipid components. This composite structure provides enhanced thermal stability and structural integrity, enabling storage under less stringent conditions compared to conventional nanoparticle formulations.
3Productivity
If single nanoparticle system is used for co-delivery, then delivery efficiency is improved, but formulation complexity worsens
Solution Approach 1:
The patent designs universal polymer-lipid hybrid nanoparticles capable of simultaneously delivering multiple therapeutic agents including nucleic acids and small molecules. This multi-functional nanoparticle platform consolidates what would otherwise require separate delivery systems, improving overall delivery efficiency while the modular design keeps formulation manageable.
Solution Approach 2:
The patent merges multiple delivery functions into a single nanoparticle formulation that can co-deliver genetic material and small molecule drugs. By combining these delivery capabilities in one unified system rather than using separate systems, the patent achieves synergistic effects and simplifies the overall therapeutic approach despite the sophisticated formulation requirements.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanoparticles provide enhanced stability and transfection efficiency, enabling dual therapy approaches with nucleic acids and small molecules, while avoiding the use of viral proteins and inducing minimal immune response.
Implementation Method 1
can be dried, e.g., lyophilized, into a shelf stable powder
Data Source
AI summary
The present disclosure provides, for instance, polymer-lipid hybrid nanoparticle compositions and methods of making and using them. The polymer-lipid hybrid nanoparticle may comprise, for example, poly(lactic-co-glycolic) acid (PLGA), polyethylenimine (PEI), and D-Lin-MC3-DMA (MC3). The polymer-lipid hybrid nanoparticle can be used to deliver, for example, nucleic acids and small molecules, cells.